Methodology and problems of protein-ligand docking: Case study of dihydroorotate dehydrogenase, thymidine kinase, and phosphodiesterase 4

Journal of Receptors and Signal Transduction

Volumn 22, Issue 1-4, 2002, Pages 141-154

  Pospisil, Pavel ^a   Kuoni, Thomas ^a   Scapozza, Leonardo ^a   Folkers, Gerd ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Aciclovir; Cofactor; Leflunomide; Molecular docking; Rolipram; Virtual screening

Indexed keywords

ACICLOVIR; BREQUINAR; CYCLIC AMP; DIHYDROOROTATE DEHYDROGENASE; LEFLUNOMIDE; PHOSPHODIESTERASE IV; PURINE; PYRIMIDINE; ROLIPRAM; TERIFLUNOMIDE; THYMIDINE; THYMIDINE KINASE; WATER;

BINDING SITE; CATALYSIS; CONFERENCE PAPER; DRUG BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; HERPES SIMPLEX VIRUS 1; HYDROPHOBICITY; LIGAND BINDING; PROTEIN BINDING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; ENZYME INHIBITORS; HUMANS; LIGANDS; MODELS, MOLECULAR; OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROTEIN BINDING; PROTEIN CONFORMATION; THYMIDINE KINASE;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0036973210     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1081/RRS-120014592     Document Type: Conference Paper

References (35)

1. Bissantz, C.; Folkers, G.; Rognan, D. Protein-Based Virtual Screening of Chemical Databases. 1. Evaluation of Different Docking/Scoring Combinations. J. Med. Chem. 2001, 43, 4759-4767.
2. Fairbanks, L.D.; Bofill, M.; Ruckemann, K.; Simmonds, H.A. Importance of Ribonucleotide Availability to Proliferating T-Lymphocytes from Healthy Humans. Disproportionate Expansion of Pyrimidine Pools and Contrasting Effects of De Novo Synthesis Inhibitors. J. Biol. Chem. 1995, 270, 29682-29689.
3. Chen, S.F.; Perrella, F.W.; Behrens, D.L.; Papp, L.M. Inhibition of Dihydroorotate Dehydrogenase Activity by Brequinar Sodium. Cancer Res. 1992, 52, 3521-3527.
4. Williamson, R.A.; Yea, C.M.; Robson, P.A.; Curnock, A.P.; Gadher, S.; Hambleton, A.B.; Woodward, K.; Bruneau, J.M.; Hambleton, P.; Moss, D.; et al. Dihydroorotate Dehydrogenase is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound. J. Biol. Chem. 1995, 270, 22467-22472.
5. Williamson, R.A.; Yea, C.M.; Robson, P.A.; Curnock, A.P.; Gadher, S.; Hambleton, A.B.; Woodward, K.; Bruneau, J.M.; Hambleton, P.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E.A.; Ruuth, E. Dihydroorotate Dehydrogenase is a Target for the Biological Effects of Leflunomide. Transplant. Proc. 1996, 28, 3088-3091.
6. Culver, K.W.; Ram, Z.; Wallbridge, S.; Ishii, H.; Oldfield, E.H.; Blaese, R.M. In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors. Science 1992, 256, 1550-1552.
7. Bonini, C.; Ferrari, G.; Verzeletti, S.; Servida, P.; Zappone, E.; Ruggieri, L.; Ponzoni, M.; Rossini, S.; Mavilio, F.; Traversari, C.; Bordignon, C. HSVTK Gene Transfer Into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia. Science 1997, 276, 1719-1724.
8. Culver, K.W.; Van Gilder, J.; Link, C.J.; Carlstrom, T.; Buroker, T.; Yuh, W.; Koch, K.; Schabold, K.; Doornbas, S.; Wetjen, B.; et al. Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Hum. Gene Ther. 1994, 5, 343-379.
9. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H.J. Selectivity of Action of an Antiherpetic Agent, 9-(2-Hydroxyethoxymethyl) Guanine. Proc. Natl. Acad. Sci. USA 1977, 74, 5716-5720.
10. Keller, P.M.; Fyfe, J.A.; Beauchamp, L.; Lubbers, C.M.; Furman, P.A.; Schaeffer, H.J.; Elion, G.B. Enzymatic Phosphorylation of Acyclic Nucleoside Analogs and Correlations with Antiherpetic Activities. Biochem. Pharmacol. 1981, 30, 3071-3077.
11. Wild, K.; Bohner, T.; Folkers, G.; Schulz, G.E. The Structures of Thymidine Kinase from Herpes Simplex Virus Type 1 in Complex with Substrates and a Substrate Analogue. Protein Sci. 1997, 6, 2097-2106.
12. Kussmann-Gerber, S.; Kuonen, O.; Folkers, G.; Pilger, B.D.; Scapozza, L. Drug Resistance of Herpes Simplex Virus Type 1-Structural Considerations at the Molecular Level of the Thymidine Kinase. Eur. J. Biochem. 1998, 255, 472-481.
13. Champness, J.N.; Bennett, M.S.; Wien, F.; Visse, R.; Summers, W.C.; Herdewijn, P.; de Clerq, E.; Ostrowski, T.; Jarvest, R.L.; Sanderson, M.R. Exploring the Active Site of Herpes Simplex Virus Type-1 Thymidine Kinase by X-Ray Crystallography of Complexes with Aciclovir and Other Ligands. Proteins 1998, 32, 350-361.
14. Bennett, M.S.; Wien, F.; Champness, J.N.; Batuwangala, T.; Rutherford, T.; Summers, W.C.; Sun, H.; Wright, G.; Sanderson, M.R. Structure to 1.9 A Resolution of a Complex with Herpes Simplex Virus Type-1 Thymidine Kinase of a Novel, Non-Substrate Inhibitor: X-Ray Crystallographic Comparison with Binding of Aciclovir. FEBS Lett. 1999, 443, 121-125.
15. Perozzo, R.; Jelesarov, I.; Bosshard, H.R.; Folkers, G.; Scapozza, L. Compulsory Order of Substrate Binding to Herpes Simplex Virus Type 1 Thymidine Kinase. A Calorimetric Study. J. Biol. Chem. 2000, 275, 16139-16145.
16. Prota, A.; Vogt, J.; Pilger, B.; Perozzo, R.; Wurth, C.; Marquez, V.E.; Russ, P.; Schulz, G.E.; Folkers, G.; Scapozza, L. Kinetics and Crystal Structure of the Wild-Type and the Engineered Y101F Mutant of Herpes Simplex Virus Type I Thymidine Kinase Interacting with (North)Methanocarba-Thymidine. Biochemistry 2000, 39, 9597-9603.
17. Livi, G.P.; Kmetz, P.; McHale, M.M.; Cieslinski, L.B.; Sathe, G.M.; Taylor, D.P.; Davis, R.L.; Torphy, T.J.; Balcarek, J.M. Cloning and Expression of cDNA for a Human Low-Km, Rolipram-Sensitive Cyclic AMP Phosphodiesterase. Mol. Cell Biol. 1990, 10, 2678-2686.
18. Conti, M.; Jin, S.L.; Monaco, L.; Repaske, D.R.; Swinnen, J.V. Hormonal Regulation of Cyclic Nucleotide Phosphodiesterases. Endocr. Rev. 1991, 12, 218-234.
19. Teixeira, M.M.; Gristwood, R.W.; Cooper, N.; Hellewell, P.G. Phosphodiesterase (PDE)4 Inhibitors: Anti-Inflammatory Drugs of the Future? Trends Pharmacol. Sci. 1997, 18, 164-171.
20. Barnette, M.S.; Underwood, D.C. New Phosphodiesterase Inhibitors as Therapeutics for the Treatment of Chronic Lung Disease. Curr. Opin. Pulm. Med. 2000, 6, 164-169.
21. Spina, D. The Potential of PDE4 Inhibitors in Asthma or COPD. Curr. Opin. Investig. Drugs 2000, 1, 204-213.
22. http://www.rcsb.org. Accessed January 2002.
23. Rarey, M.; Kramer, B.; Lengauer, T. Time-Efficient Docking of Flexible Ligands into Active Sites of Proteins. Ismb 1995, 3, 300-308.
24. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX Incremental Construction Algorithm for Protein-Ligand Docking. Proteins 1999, 37, 228-241.
25. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
26. Oshiro, C.M.; Kuntz, I.D.; Dixon, J.S. Flexible Ligand Docking Using a Genetic Algorithm. J. Comput. Aid. Mol. Des. 1995, 9, 113-130.
27. www.library.wisc.edu/help/quickguide/acd.htm (Accessed January 2002)
28. www.tripos.com/software/cscore_print.html (Accessed January 2002)
29. Liu, S.; Neidhardt, E.A.; Grossman, T.H.; Ocain, T.; Clardy, J. Structures of Human Dihydroorotate Dehydrogenase in Complex with Antiproliferative Agents. Struct. Fold. Des. 2000, 8, 25-33.
30. McLean, J.E.; Neidhardt, E.A.; Grossman, T.H.; Hedstrom, L. Multiple Inhibitor Analysis of the Brequinar and Leflunomide Binding Sites on Human Dihydroorotate Dehydrogenase. Biochemistry 2001, 40, 2194-2200.
31. Pospisil, P.; Scapozza, L.; Folkers, G. The Role of Water in Drug Design: Thymidine Kinase as Case Study. In Rational Approaches to Drug Design. 13th European Symposium on Quantitative Structure-Activity Relationship; Höltje, H.-D. and Sippl, W., Eds.; Prous Science: Barcelona-Philadelphia, 2001; 92-96.
32. Dym, O.; Xenarios, I.; Ke, H.; Colicelli, J. Molecular Docking of Competitive Phosphodiesterase Inhibitors. Mol. Pharmacol. 2002, 61, 20-25.
33. Xu, R.X.; Hassell, A.M.; Vanderwall, D.; Lambert, M.H.; Holmes, W.D.; Luther, M.A.; Rocque, W.J.; Milburn, M.V.; Zhao, Y.; Ke, H.; Nolte, R.T. Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity. Science 2000, 288, 1822-1825.
34. Laliberte, F.; Han, Y.; Govindarajan, A.; Giroux, A.; Liu, S.; Bobechko, B.; Lario, P.; Bartlett, A.; Gorseth, B.; Gresser, M.; Huang, Z. Conformational Difference Between PDE4 Apoenzyme and Holoenzyme. Biochemistry 2000, 39, 6449-6458.
35. Beese, L.S.; Steitz, T.A. Structural Basis for the 3′-5′ Exonuclease Activity of Escherichia Coli DNA Polymerase 1: A Two Metal Ion Mechanism. EMBO J. 1991, 10, 25-33.